Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | CNR2 | P34972 | 9/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929059 | 1.00 | KCNH2 (0.44) | KCNH2CNR2HCRTR1HCRTR2MEN1 | |
| SCHEMBL4937187 | 0.85 | HDAC3 (0.52) | HDAC3HDAC1HDAC10HDAC6 | |
| SCHEMBL4926659 | 0.85 | HDAC3 (0.52) | HDAC3HDAC1HDAC10HDAC6 | |
| SCHEMBL4926676 | 0.85 | HDAC3 (0.52) | HDAC3HDAC1HDAC10HDAC6 | |
| SCHEMBL4930747 | 0.84 | HDAC1 (0.40) | KCNH2POLBHDAC1HDAC6 | |
| SCHEMBL4930759 | 0.84 | HDAC1 (0.40) | KCNH2POLBHDAC1HDAC6 | |
| SCHEMBL4930316 | 0.81 | HDAC1 (0.42) | MEN1KMT2AHDAC3HDAC1HDAC10 | |
| SCHEMBL4930303 | 0.81 | HDAC1 (0.42) | MEN1KMT2AHDAC3HDAC1HDAC10 | |
| SCHEMBL4934917 | 0.80 | HDAC1 (0.43) | KCNH2CNR2MEN1KMT2AHDAC3 | |
| SCHEMBL4934905 | 0.80 | HDAC1 (0.43) | KCNH2CNR2MEN1KMT2AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | KUREHA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1707560-A1 | HYDROXAMIC ACID DERIVATIVE AND AGE GENERATION INHIBITOR CONTAINING THE DERIVATIVE | Kureha Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | HDAC5, HDAC1, HDAC9 | KCNH2 4725/4885CNR2 4827/4885HCRTR1 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.